Carregant...

HER2 mutated breast cancer responds to treatment with single agent neratinib, a second generation HER2/EGFR tyrosine kinase inhibitor

Activating mutations in the HER2 tyrosine kinase have been identified in human breast cancers that lack HER2 gene amplification. These patients are not candidates for HER2 targeted drugs under current standards of care, but preclinical data strongly suggest that these patients will benefit from anti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Natl Compr Canc Netw
Autors principals: Ben–Baruch, Noa Efrat, Bose, Ron, Kavuri, Shyam M., Ma, Cynthia X., Ellis, Matthew J.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4701428/
https://ncbi.nlm.nih.gov/pubmed/26358790
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!